National adverse event reporting for medical devices in Israel, 2013-2024.

IF 2.4 4区 医学 Q1 HEALTH POLICY & SERVICES
Meital Mishali, Nadav Sheffer, Maya Negev
{"title":"National adverse event reporting for medical devices in Israel, 2013-2024.","authors":"Meital Mishali, Nadav Sheffer, Maya Negev","doi":"10.1186/s13584-026-00776-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Post-market surveillance systems are essential for identifying medical device-related adverse events and ensuring patient safety. In Israel, the Ministry of Health has operated a national medical device reporting system for decades. The system is modeled on United States and European regulatory frameworks, although the Medical Devices Act has not yet entered into force.</p><p><strong>Methods: </strong>Following formal approval, anonymized aggregate data were obtained from the Ministry of Health Medical Device Division for reports submitted between 2013 and 2024. The dataset included annual reporting volumes, report classification as adverse events or Field Safety Notices, reporting source, and event type (death, injury, or malfunction), where available. Availability varied across the study period; analyses were therefore restricted to years in which the relevant variables were recorded.</p><p><strong>Results: </strong>Overall reporting volumes increased over time, from 406 in 2013 to 874 in 2024. Non-linear trends were observed, with declines in 2017, 2020, 2022, and 2024. Since 2019, adverse events accounted for approximately 61.9-75.5% of reports annually, while Field Safety Notices comprised 21.4-33.3%. From 2022 onward, most adverse events were classified as injuries, increasing from 87.1% in 2022 to 89.8% in 2023 and remaining high at 89.1% in 2024. Malfunctions accounted for 10.3% of adverse events in 2022, 7.9% in 2023, and 8.5% in 2024, whereas deaths remained relatively stable at 2.2-2.5%. Reporting was dominated by registration holders (70-80%), primarily importers and distributors, followed by manufacturers, with consistently limited contributions from healthcare institutions and voluntary reporters.</p><p><strong>Conclusions: </strong>This analysis of Israel's national medical device reporting database provides an empirical baseline for assessing the structure and functioning of the country's post-market surveillance system. Increasing reporting activity and improved event classification indicate system maturation. The predominance of reports from registration holders, alongside more limited participation by healthcare institutions and voluntary reporters, points to areas for continued development. The following measures would strengthen post-market surveillance in Israel: full implementation of the legal framework; clearer reporting responsibilities and pathways: targeted guidance and training; electronic reporting and analytical tools; improved event documentation; and structured feedback and transparency mechanisms.</p>","PeriodicalId":46694,"journal":{"name":"Israel Journal of Health Policy Research","volume":"15 1","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13501563/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Israel Journal of Health Policy Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13584-026-00776-x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Post-market surveillance systems are essential for identifying medical device-related adverse events and ensuring patient safety. In Israel, the Ministry of Health has operated a national medical device reporting system for decades. The system is modeled on United States and European regulatory frameworks, although the Medical Devices Act has not yet entered into force.

Methods: Following formal approval, anonymized aggregate data were obtained from the Ministry of Health Medical Device Division for reports submitted between 2013 and 2024. The dataset included annual reporting volumes, report classification as adverse events or Field Safety Notices, reporting source, and event type (death, injury, or malfunction), where available. Availability varied across the study period; analyses were therefore restricted to years in which the relevant variables were recorded.

Results: Overall reporting volumes increased over time, from 406 in 2013 to 874 in 2024. Non-linear trends were observed, with declines in 2017, 2020, 2022, and 2024. Since 2019, adverse events accounted for approximately 61.9-75.5% of reports annually, while Field Safety Notices comprised 21.4-33.3%. From 2022 onward, most adverse events were classified as injuries, increasing from 87.1% in 2022 to 89.8% in 2023 and remaining high at 89.1% in 2024. Malfunctions accounted for 10.3% of adverse events in 2022, 7.9% in 2023, and 8.5% in 2024, whereas deaths remained relatively stable at 2.2-2.5%. Reporting was dominated by registration holders (70-80%), primarily importers and distributors, followed by manufacturers, with consistently limited contributions from healthcare institutions and voluntary reporters.

Conclusions: This analysis of Israel's national medical device reporting database provides an empirical baseline for assessing the structure and functioning of the country's post-market surveillance system. Increasing reporting activity and improved event classification indicate system maturation. The predominance of reports from registration holders, alongside more limited participation by healthcare institutions and voluntary reporters, points to areas for continued development. The following measures would strengthen post-market surveillance in Israel: full implementation of the legal framework; clearer reporting responsibilities and pathways: targeted guidance and training; electronic reporting and analytical tools; improved event documentation; and structured feedback and transparency mechanisms.

2013-2024年以色列医疗器械国家不良事件报告。
背景:上市后监测系统对于识别医疗器械相关不良事件和确保患者安全至关重要。在以色列,卫生部几十年来一直在运行一个国家医疗器械报告系统。该系统以美国和欧洲的监管框架为蓝本,尽管《医疗器械法》尚未生效。方法:经正式批准,从卫生部医疗器械司获取2013年至2024年提交的报告的匿名汇总数据。数据集包括年度报告量、报告分类为不良事件或现场安全通知、报告来源和事件类型(死亡、伤害或故障)(如有)。在整个研究期间,可用性各不相同;因此,分析仅限于记录相关变量的年份。结果:总体报告量随着时间的推移而增加,从2013年的406份增加到2024年的874份。观察到非线性趋势,分别在2017年、2020年、2022年和2024年下降。自2019年以来,不良事件约占年度报告的61.9-75.5%,而现场安全通知占21.4-33.3%。从2022年开始,大多数不良事件被归类为伤害,从2022年的87.1%上升到2023年的89.8%,并在2024年保持在89.1%的高位。2022年,故障占不良事件的10.3%,2023年为7.9%,2024年为8.5%,而死亡相对稳定在2.2% -2.5%。报告主要由注册持有人(70-80%),主要是进口商和分销商,其次是制造商,医疗机构和自愿报告者的贡献一直有限。结论:对以色列国家医疗器械报告数据库的分析为评估该国上市后监测系统的结构和功能提供了经验基线。增加报告活动和改进事件分类表明系统成熟。登记持有人的报告占主导地位,加上医疗机构和自愿报告者的参与更为有限,这表明了需要继续发展的领域。以下措施将加强以色列的上市后监督:充分执行法律框架;更明确的报告责任和途径:有针对性的指导和培训;电子报告和分析工具;改进的事件文档;以及结构化的反馈和透明机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.20
自引率
4.40%
发文量
38
审稿时长
28 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书